Lupin launches Sevelamer Hydrochloride tablets in US
The product will be manufactured at Lupin’s facility in Nagpur
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Lupin
Lupin announces executive leadership change
Dr Fabrice Egros to assume Corporate Development responsibilities as President, Corporate Development and Growth Markets
Lupin gets FDA approval of sNDA for Solosec
The supplemental adolescent approval enhances Solosec's strong position as the first and only single-dose oral prescription…
Lupin signs distribution agreement with Medis for orphan drug NaMuscla
The agreement enables expanded patient access of the only EU-approved treatment for myotonia symptoms in non-dystrophic myotonic…
Lupin receives approval from US FDA for Arformoterol Tartrate inhalation solution
Arformoterol Tartrate inhalation solution 15 mcg (base)/2 ml, unit-dose vials are indicated for the long-term maintenance…
Lupin and Axantia enter into license-, supply- and technology-sharing agreement for Pegfilgrastim
Under the terms of the agreement, Axantia will register, distribute and market biosimilar Pegfilgrastim drug product in certain…
Lupin inks pact with Exeltis to promote Solosec drug in US
As part of the tie-up, Exeltis will promote Solosec along with its existing line of women's health products
Lupin signs first partnership agreement with Foncoo for China
This is Lupin’s first partnership arrangement in China and reinforces its commitment to bring high-quality generic and complex…
Lupin launches Molnupiravir under brand name Molnulup to treat COVID-19
Clinical data suggests that it is effective on patients with co-morbidities
Lupin gets tentative US FDA nod for generic tablets to treat high BP
These are generic equivalent of Edarbi tablets, 40 mg and 80 mg of Arbor Pharmaceuticals, LW